In-vivo Imaging Market size is poised to reach USD 6 Billion by the end of 2036, growing at a rate of 6% during the forecast period, i.e., 2024 – 2036. In the year 2023, the industry size of in-vivo imaging was USD 3 Billion. The reason behind the growth is impelled by the increasing cases of cancer across the globe. Cancer is the primary cause of death, and in nations with low Human Development Indexes (HDI), the number of new cases is rising rapidly.
In the study of cancer biology as well as in clinical prognosis and treatment, In-vivo imaging has emerged as a crucial tool as it offers one-of-a-kind, cutting-edge capabilities to help with the development of protocols for cancer detection and diagnosis.
According to estimates, by 2040, there will be more than 26 million new instances of cancer annually throughout the world.
The rising trend of precision medicine is believed to fuel the market growth. Precision medicine has helped reduce superfluous, pointless testing and unnecessary hospital admissions and has led to more accurate diagnoses and forecasts of disease risk before any symptoms appear.
Moreover, precision medicine is an effective method for examining the human body in vivo molecular imaging, which allows for more accurate diagnostics and real-time monitoring.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~6% |
|
Base Year Market Size (2023) |
~ USD 3 Billion |
|
Forecast Year Market Size (2036) |
~ USD 6 Billion |
|
Regional Scope |
|
Modality (Nuclear Imaging Systems, Optical Imaging Systems, Micro-MRI, Micro-Ultrasound, Micro-CT, Photoacoustic Imaging Systems, Magnetic Particle Imaging Systems)
The micro-MRI segment is estimated to hold 21% share of the global in-vivo imaging market in the coming years owing to the growing usage in small animal imaging. In vivo, 3D imaging of microstructure in small animals such as mice and rats is made easier with the use of micro-MRI since small animal models play a crucial role in cardiovascular investigation and help researchers in studying In-vivo molecular pathways in cardiovascular pathology.
Techniques (Biomarkers Based, Luminescent Proteins Based, Radioisotopes Based)
The radioisotopes based segment is set to garner a notable share shortly. Radioisotope-based based In-vivo imaging is widely used in preclinical research to study diseases in living organisms. For instance, positron emission tomography (PET) is an imaging technique that uses radioisotopes to inject a small amount of radioactive glucose into the veins of animals to study metabolic processes and more.
Our in-depth analysis of the global market includes the following segments:
|
Modality |
|
|
Techniques |
|
|
End-User |
|
|
Reagents |
|
APAC Market Forecast
In-vivo imaging market in Asia Pacific is predicted to account for the largest share of 46% by 2036 impelled by the increasing spending in healthcare. This has led to the expansion of research & development activities in healthcare technology in the region, which might result in the development of more advanced In-vivo imaging techniques. According to estimates, the predicted cost of healthcare in India in 2020 was more than USD 190 billion.
North American Market Statistics
The North America In-vivo imaging market is estimated to be the second largest, during the forecast timeframe led by the presence of well-established healthcare infrastructure. The American economy's most important sector is the healthcare industry which focuses on cutting costs and enhancing patient outcomes. As a result, the availability of skilled medical professionals and advanced diagnostic techniques including for more precise diagnosis of diseases has increased in the region. This is expected to create huge demand for In-vivo imaging techniques.
Author Credits: Radhika Gupta, Shivam Bhutani
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?